Elan completes $101.8m sale
Elan Pharmaceutical has completed the sale of its four pain products and related assets to aaiPharma Inc for $101.8m.(€83.6m).
This includes the rights to its Roxicodone, Roxanol and Duraclon products.
The Business Hub
Newsletter
News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.





